Provided are compositions and methods for introducing proteins into cells. The compositions and methods relate to introducing a foreign protein as an engineered component of a paramyxovirus virus like particle (VLP). The compositions and methods pertain to modified VLPs that contain a contiguous recombinant polypeptide comprising i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein that is an enzyme such as a recombinase.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The present disclosure relates to a novel anti-respiratory syncytial virus (RSV) monoclonal antibody, a method for preparing the antibody, and related applications thereof for immunoassay. The anti-RSV monoclonal antibody of the present disclosure exhibits high sensitivity and high specificity against RSV, and thus can be used for RSV detection at a nanoscale concentration on a chromatographic platform, and achieve more sensitive detection at a picoscale concentration in other platforms such as those for chemiluminescent assays.

The present disclosure relates to a novel anti-respiratory syncytial virus (RSV) monoclonal antibody, a method for preparing the antibody, and related applications thereof for immunoassay. The anti-RSV monoclonal antibody of the present disclosure exhibits high sensitivity and high specificity against RSV, and thus can be used for RSV detection at a nanoscale concentration on a chromatographic platform, and achieve more sensitive detection at a picoscale concentration in other platforms such as those for chemiluminescent assays.

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Respiratory Syncytial Virus antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Respiratory Syncytial virus infection in a subject using the composition and method of generation.

The present invention relates to methods and compositions for engineering B cells to express transgenic B cell receptor (BCR) for antigen-induced antibody secretion, compositions, methods and uses thereof in immunotherapy.